Triple Negative Breast Cancer: ASCO Tumor Boards

Product ID : TBC17
Price: $15.00
You will receive a link to your product from within 1 hour of purchase confirmation. Shipping charges do not apply to digital products.
E-mail to a friend



Shopping Cart Description (limit 2,000 characters including spaces):   This is a case-based activity that includes discussion of two patients with triple negative breast cancer. The first is a 34-year-old woman who presented with a 6cm mass in the upper outer quadrant of her left breast. On exam, she was noted to have two palpable 2cm hard left axillary lymph nodes. A biopsy of the breast mass reveals grade 3 invasive ductal breast cancer, ER 0, PR 0, HER2 1+ and FISH negative. PET CT scan shows no evidence of metastatic disease outside of the left axillary and subpectoral lymph nodes. The second patient is a 42-year-old woman with an enlarging breast mass and breast erythema. Imaging reveals an 8 x 9 cm mass with skin induration and questionable abnormal nodes. Biopsy reveals high grade invasive ductal cancer.


At the end of this course, learners should be able to:

  • Review the evidence supporting current systemic therapy options for early stage TNBC
  • Discuss systemic therapies that can improve disease-free survival in patients with locally advanced TNBC
  • Evaluate the standard and emerging therapies of benefit for patients with metastatic TNBC


IMPORTANT NOTE: This course expires on April 27, 2020. Participants must complete all necessary course components by this date.


Purchase the 2017 ASCO Tumor Boards Bundle to access to all 2017 ASCO Tumor Boards for added savings. Purchased separately, these items would be $180 altogether. When bundled, you save $55.